RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Nephpearls #VisualAbstract by @kidney_boy 👉🏼 https://t.co/tjweNX4oNp https://t.co/K91blSESt7

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

RT @edgarvlermamd: @NavTangri @NephJC @hswapnil @kidney_boy @Nephro_Sparks Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we ha…

RT @edgarvlermamd: @NavTangri @NephJC @hswapnil @kidney_boy @Nephro_Sparks Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we ha…

@NavTangri @NephJC @hswapnil @kidney_boy @Nephro_Sparks Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Nephpearls #AskRenal #VisualAbstract by @kidney_boy 👉🏼 https://t.co/tjweNX4oNp h

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

Journal club ✅ https://t.co/pO8ZE6d084

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

RT @NephroGuy: This is the new stuff for diabetes treatments @aldorodrigo https://t.co/VIPNTzCRcz

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

This is the new stuff for diabetes treatments @aldorodrigo https://t.co/VIPNTzCRcz

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

Impressive tweeting from @edgarvlermamd 👇 https://t.co/YOqe6Jn9uC

RT @edgarvlermamd: Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Ne…

Rise of the SGLT2 inhibitors: First, we had EMPA-REG, then we had CANVAS... now we have CREDENCE from @VladoPerkovic #Nephpearls #VisualAbstract by @kidney_boy 👉🏼 https://t.co/nlwtZc5HYk https://t.co/XZkUZ6De22

RT @edgarvlermamd: MT @aakashshingada @divyaa24 @krishnadoctor1 New anti-diabetic agents - cardioprotective and/ or renoprotective ⁉️ #ASN_…

RT @edgarvlermamd: MT @aakashshingada @divyaa24 @krishnadoctor1 New anti-diabetic agents - cardioprotective and/ or renoprotective ⁉️ #ASN_…

RT @edgarvlermamd: MT @aakashshingada @divyaa24 @krishnadoctor1 New anti-diabetic agents - cardioprotective and/ or renoprotective ⁉️ #ASN_…

RT @edgarvlermamd: MT @aakashshingada @divyaa24 @krishnadoctor1 New anti-diabetic agents - cardioprotective and/ or renoprotective ⁉️ #ASN_…

RT @edgarvlermamd: MT @aakashshingada @divyaa24 @krishnadoctor1 New anti-diabetic agents - cardioprotective and/ or renoprotective ⁉️ #ASN_…

RT @edgarvlermamd: MT @aakashshingada @divyaa24 @krishnadoctor1 New anti-diabetic agents - cardioprotective and/ or renoprotective ⁉️ #ASN_…

Watch out for the numerous trials(completed as well as ongoing) on Sglt2i, Dpp4i and glp1 agonists! #ASN_HL18 #Nephpearls https://t.co/HKmDeH9XXk

RT @edgarvlermamd: MT @aakashshingada @divyaa24 @krishnadoctor1 New anti-diabetic agents - cardioprotective and/ or renoprotective ⁉️ #ASN_…

MT @aakashshingada @divyaa24 @krishnadoctor1 New anti-diabetic agents - cardioprotective and/ or renoprotective ⁉️ #ASN_HL18 🇮🇳 #Nephpearls 👉🏼 https://t.co/tjweNX4oNp https://t.co/1hcg4sV2Dk

RT @edgarvlermamd: Completed and ongoing CV outcome trials in Diabetes #Nephpearls 👉🏼 https://t.co/sfN9926XMC https://t.co/WFEjUQA9eB

RT @edgarvlermamd: Completed and ongoing CV outcome trials in Diabetes #Nephpearls 👉🏼 https://t.co/sfN9926XMC https://t.co/WFEjUQA9eB

RT @edgarvlermamd: Completed and ongoing CV outcome trials in Diabetes #Nephpearls 👉🏼 https://t.co/sfN9926XMC https://t.co/WFEjUQA9eB

RT @edgarvlermamd: Completed and ongoing CV outcome trials in Diabetes #Nephpearls 👉🏼 https://t.co/sfN9926XMC https://t.co/WFEjUQA9eB

RT @edgarvlermamd: Completed and ongoing CV outcome trials in Diabetes #Nephpearls 👉🏼 https://t.co/sfN9926XMC https://t.co/WFEjUQA9eB

RT @edgarvlermamd: Completed and ongoing CV outcome trials in Diabetes #Nephpearls 👉🏼 https://t.co/sfN9926XMC https://t.co/WFEjUQA9eB

Advances in the management of cardiovascular risk for patients with T2DM via @DovePress https://t.co/YQAZZ0LWYC

RT @edgarvlermamd: Completed and ongoing CV outcome trials in Diabetes #Nephpearls 👉🏼 https://t.co/sfN9926XMC https://t.co/WFEjUQA9eB

Completed and ongoing CV outcome trials in Diabetes #Nephpearls 👉🏼 https://t.co/sfN9926XMC https://t.co/WFEjUQA9eB